"We believe that the patent in question is invalid and thwarts the spirit of innovation," stated Dr. David Tran, Founding Scientist at Fustibal. "The IPR process is being utilized to clear questionable intellectual property rights that would unduly delay the development of our novel antibody-based drug for multi-targeted cancer therapy. We believe oncology products should be developed and accessible to all cancer patients, not only for those patients who can afford it. We look forward to the uninterrupted development of medicine, whether innovative or generic, and the submission of New Drug Application (NDA) and Abbreviated NDA (ANDA) for future formulations."
The first petition for inter partes review is assigned the processing number IPR2016-01490 by the United States Patent and Trademark Office's PTAB.
Fustibal is a biotechnology company focused on fostering affordable healthcare through simpler science. To evolve the medical industry, our team dissects life science big data through scientific investigation, reverse engineering, data mining, and computational science. In synergy with our Drug Targeting Platform, we design genomic- and proteomic-driven pharmaceuticals. Our mission is to develop data-based computational and accessible molecular diagnostics and therapeutics. Learn more at fustibal.com and twitter.com/fustibal.
David Tran, PhD
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bayers-stivarga-patent-challenged-in-inter-partes-review-300304316.html
SOURCE Fustibal LLC